48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
Crossref DOI link: https://doi.org/10.1186/1471-2334-14-S2-P72
Published Online: 2014-05-23
Published Print: 2014-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yazdanpanah, Y
Khuong-Josses, M-A
Hocqueloux, L
Pialoux, G
Durant, J
Wynne, B
Granier, C
Tebas, P
Pappa, K
Min, S
Article History
First Online: 23 May 2014